IDEAYA Biosciences, Inc. (IDYA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IDYA currently has 88.7M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 19.12% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 88.7M shares outstanding |
89M | 0 |
| Nov 04, 2025 |
10-Q filing | 88.5M shares outstanding |
89M | 0 |
| Aug 05, 2025 |
10-Q filing | 88.5M shares outstanding |
88M | 0 |
| May 06, 2025 |
10-Q filing | 88.4M shares outstanding |
88M | 0 |
| Feb 18, 2025 |
10-K filing | 81.7M shares outstanding |
82M | 0 |
| Nov 04, 2024 |
10-Q filing | 86.2M shares outstanding |
86M | 0 |
| Aug 06, 2024 |
10-Q filing | 78.0M shares outstanding |
78M | 0 |
| May 07, 2024 |
10-Q filing | 75.1M shares outstanding |
75M | 0 |
| Feb 20, 2024 |
10-K filing | 74.6M shares outstanding |
75M | 0 |
| Jan 23, 2024 |
8-K filing: IDEAYA Biosciences, Inc. sold 3,119,866 shares of common stock for net proceeds of $126.9 million at a weighted average price of $41.50 per share under an at-the-market offering pursuant to the January 2024 Sales Agreement. ($126.9M proceeds) |
60M | 0 |
| Jan 16, 2024 |
8-K filing: IDEAYA Biosciences, Inc. completed an at-the-market offering on January 12, 2024, selling 1,561,735 shares for net proceeds of $57.0 million at a weighted average price of $37.60 per share under the June 2023 Sales Agreement, and no further shares are available for sale under this agreement as of January 15, 2024. ($57.0M proceeds) |
60M | 0 |
| Nov 07, 2023 |
10-Q filing | 60.0M shares outstanding |
60M | 0 |
| Aug 10, 2023 |
10-Q filing | 56.3M shares outstanding |
56M | 0 |
| Jun 09, 2023 |
8-K filing: The Company's Board of Directors approved the amendment of the Company's Non-Employee Director Compensation Program to increase the number of shares of the Company's common stock purchasable under the Initial Stock Option Grant and the Annual Stock Option Grant. |
48M | 0 |
| May 09, 2023 |
10-Q filing | 48.4M shares outstanding |
48M | 0 |
| Mar 07, 2023 |
10-K filing | 48.4M shares outstanding |
48M | 0 |
| Nov 08, 2022 |
10-Q filing | 48.1M shares outstanding |
48M | 0 |
| Aug 15, 2022 |
10-Q filing | 38.7M shares outstanding |
39M | 0 |
| May 10, 2022 |
10-Q filing | 38.6M shares outstanding |
39M | 0 |
| Mar 18, 2022 |
10-K filing | 38.6M shares outstanding |
39M | 0 |
| Nov 15, 2021 |
10-Q filing | 38.5M shares outstanding |
38M | 0 |
| Aug 10, 2021 |
10-Q filing | 38.4M shares outstanding |
38M | 0 |
| May 10, 2021 |
10-Q filing | 32.9M shares outstanding |
33M | 0 |
| Mar 23, 2021 |
S-3 filing: IDEAYA Biosciences, Inc. files an S-3 registration statement to offer and sell up to $400,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
29M | 0 |
| Mar 23, 2021 |
10-K filing | 32.3M shares outstanding |
32M | 0 |
| Nov 12, 2020 |
10-Q filing | 29.1M shares outstanding |
29M | 0 |
| Aug 12, 2020 |
10-Q filing | 29.0M shares outstanding |
29M | 0 |
| Jun 01, 2020 |
S-3 filing: IDEAYA Biosciences, Inc. may offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
20M | 52K |
| May 12, 2020 |
10-Q filing | 20.4M shares outstanding |
20M | 0 |
| Mar 24, 2020 |
10-K filing | 20.3M shares outstanding |
20M | 0 |